PDGFR-beta Inhibitors
Santa Cruz Biotechnology now offers a broad range of PDGFR-beta Inhibitors. The biological effects of Platelet-derived growth factor (PDGF) proteins are mediated via two tyrosine kinase receptors, PDGFR-α and PDGFR-β. PDGF-mediated signaling is critical for development of many organ systems and is important for growth and survival. PDGFR-beta Inhibitors offered by Santa Cruz inhibit PDGFR-beta and, in some cases, other development and tyrosine kinase receptor related proteins. View detailed PDGFR-beta Inhibitor specifications, including PDGFR-beta Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 41 to 44 of 44 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Motesanib | 453562-69-1 | sc-391480 | 5 mg | $290.00 | ||
Motesanib functions as a selective antagonist of PDGFR-beta, characterized by its ability to form stable complexes through specific electrostatic interactions and steric hindrance. This compound modulates receptor activity by interfering with downstream signaling cascades, leading to altered cellular responses. Its unique binding affinity results in a distinctive kinetic profile, marked by a slow off-rate that enhances its regulatory effects on cellular processes. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, Free Base acts as a potent inhibitor of PDGFR-beta, exhibiting a unique binding mechanism that involves hydrophobic interactions and hydrogen bonding. This compound disrupts the receptor's conformational dynamics, influencing the activation of associated signaling pathways. Its distinct molecular architecture allows for prolonged engagement with the target, resulting in a notable alteration in reaction kinetics and cellular signaling outcomes. The compound's solubility characteristics further enhance its interaction profile within biological systems. | ||||||
Vatalanib Dihydrochloride | 212141-51-0 | sc-202379 sc-202379A | 5 mg 25 mg | $125.00 $374.00 | ||
Vatalanib Dihydrochloride functions as a selective antagonist of PDGFR-beta, characterized by its ability to modulate receptor dimerization and downstream signaling cascades. Its unique structural features facilitate specific electrostatic interactions, promoting a stable binding conformation. This compound exhibits a distinct kinetic profile, leading to altered phosphorylation states of target proteins, which can significantly impact cellular behavior. Additionally, its solubility properties enhance its distribution in various environments. | ||||||
Sorafenib Tosylate | 475207-59-1 | sc-357801 sc-357801A | 100 mg 1 g | $104.00 $312.00 | 16 | |
Sorafenib Tosylate acts as a potent inhibitor of PDGFR-beta, distinguished by its ability to disrupt receptor autophosphorylation and subsequent signaling pathways. The compound's unique molecular architecture allows for specific hydrophobic interactions, enhancing binding affinity. Its kinetic behavior is marked by a rapid onset of action, influencing the phosphorylation dynamics of associated proteins. Furthermore, its physicochemical properties contribute to its stability in diverse conditions, affecting its overall reactivity. | ||||||